Actively Recruiting

Phase 2
Age: 18Years +
All Genders
NCT05694312

Ibrutinib for the Treatment of AIHA in Patients With CLL/SLL or CLL-like MBL

Led by Gruppo Italiano Malattie EMatologiche dell'Adulto · Updated on 2023-12-01

45

Participants Needed

3

Research Sites

153 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This is a multicenter, single arm, phase II study aimed at evaluating ibrutinib therapy for the treatment of AIHA in patients with CLL/SLL or CLL-like MBL.

CONDITIONS

Official Title

Ibrutinib for the Treatment of AIHA in Patients With CLL/SLL or CLL-like MBL

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Diagnosis of CLL, small lymphocytic lymphoma (SLL), or CLL-like monoclonal B-cell lymphocytosis (MBL) based on IWCLL guidelines
  • Age over 18 years
  • Active autoimmune hemolytic anemia (AIHA) that is relapsed after corticosteroid treatment, steroid-resistant, or steroid-dependent requiring more than 10 mg/day of predniso(lo)ne
  • AIHA defined by anemia with hemoglobin ≤10 g/dL or requiring transfusions, plus laboratory evidence of hemolysis and positive direct antiglobulin test (DAT)
  • For DAT-negative active AIHA, eligibility must be confirmed by the study investigators
  • Signed informed consent according to applicable guidelines and laws
Not Eligible

You will not qualify if you...

  • Contraindications to ibrutinib therapy as determined by the treating physician
  • Contraindications listed in the ibrutinib data sheet, including severe liver impairment, allergy to the drug or excipients, or use of warfarin or vitamin K antagonists
  • Previous treatment with ibrutinib for CLL
  • Current treatment for CLL/SLL or AIHA other than corticosteroids
  • Female patients who are pregnant, planning pregnancy, or breastfeeding

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 3 locations

1

Ematologia Osp Careggi

Florence, Italy

Actively Recruiting

2

Ematologia Osp Maggiore della Carità

Novara, Italy

Actively Recruiting

3

Ematologia Osp Molinette

Torino, Italy

Actively Recruiting

Loading map...

Research Team

P

Paola Fazi

CONTACT

E

Enrico Crea

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

TREATMENT

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here